GlassScriptPhysician profile
Richard P Crane
NPI 1376647685
$7,897.57
in general payments reported to CMS, 2019-2025
29 companies · $2,940 in 2025
The $2,940 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $68.18 · 2021: $152 · 2022: $204 · 2023: $1,581 · 2024: $2,745 · 2025: $2,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,265.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,722.06 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $850.80 | 2021-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $807.37 | 2023-2025 | |
| Abbvie INC. | $648.79 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $431.13 | 2023-2025 | Taltz, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $418.76 | 2024-2025 | Saphnelo, Fasenra |
| Novartis Pharmaceuticals Corporation | $292.86 | 2020-2025 | |
| Glaxosmithkline, LLC. | $262.94 | 2024-2025 | Benlysta |
| Organon LLC | $219.02 | 2023-2025 | Hadlima |
| Ucb, INC. | $184.78 | 2025 | Bimzelx |
| Genentech USA, INC. | $138.52 | 2023-2025 | Actemra |
| Scilex Pharmaceuticals INC. | $134.16 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $131.85 | 2024-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $95.82 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.44 | 2023 | Cyltezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $68.85 | 2024 | Arcalyst |
| Invivyd INC | $54.73 | 2025 | Pemgarda |
| Tonix Medicines, INC. | $52.32 | 2025 | Tonmya |
| Sandoz INC. | $50.54 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $43.50 | 2021-2025 | Strensiq |
| Kiniksa Pharmaceuticals, LTD. | $34.81 | 2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $31.32 | 2025 | |
| Bioventus LLC | $26.62 | 2023 | Durolane |
| Actelion Pharmaceuticals US, INC. | $24.05 | 2025 | Opsynvi |
| Sobi, INC | $22.11 | 2025 | |
| Novo Nordisk INC | $17.51 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $16.72 | 2025 | |
| Hikma Pharmaceuticals USA | $16.26 | 2023 | Mitigare |
| Horizon Therapeutics Plc | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.